Today NIH announced the launch of #ACTIV-2 (outpatient) Phase 2/3 and ACTIV-3 (inpatient) Phase 3 clinical trials investigating the use of monoclonal antibodies as a potential treatment for #COVID19. Antibodies are molecules our immune systems use to fight germs. People recovered from #COVID19 can produce antibodies. Researchers can examine blood samples from COVID-19 survivors & isolate antibodies. Scientists then create lab-engineered copies, thus making monoclonal antibodies. | National Insti

For patients with moderately to severely active ulcerative colitis, the efficacy and safety of the anti-TL1A monoclonal antibody tulisokibart is unknown. Results of a phase 2 trial are summarized in a new Quick Take video. https://nej.md/4gCAts6 | The New England Journal of Medicine